Previously, Timothy designed and led Wellcome’s strategic priority area for combatting drug-resistant infections, deploying a budget of over £250 million. He was also responsible for a portfolio of Wellcome projects to support early-stage product development, which covered therapeutics, diagnostic and devices across several therapeutic areas, particularly infectious diseases and oncology.
Prior to joining Wellcome in 2012, Timothy accumulated over a decade of industry experience both in biologic therapeutic research and development and latterly as a consultant providing business development, licensing and commercial research services.
He is a chemist-turned-molecular biologist, who holds a BSc Chemistry from the University of Georgia, and masters and PhD from Princeton University. In his academic career, he acquired extensive academic research experience at Harvard Medical School, Dana Farber Cancer Institute and the MRC National Institute for Medical Research.